For research use only. Not for therapeutic Use.
Gacyclidine, also known as OTO-311 and GK-11, is a N-methyl-D-aspartate (NMDA) receptor antagonist potentially for the treatment of tinnitus. Local administration of gacyclidine to the cochlea can suppress salicylate-induced tinnitus. Tritiated gacyclidine and its enantiomers bind to NMDA receptors with binding parameters similar to those of other non-competitive NMDA receptor antagonists.
| Catalog Number | I006927 |
| CAS Number | 68134-81-6 |
| Synonyms | Gacyclidine; OTO-311; GK-11; OTO 311; GK 11; OTO311; GK11;1-((1S,2S)-2-methyl-1-(thiophen-2-yl)cyclohexyl)piperidine |
| Molecular Formula | C16H25NS |
| Purity | ≥95% |
| Target | N-methyl-D-aspartate Receptor Antagonist |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4°C for short term or -20 °C for long term |
| IUPAC Name | 1-[(1R,2S)-2-methyl-1-thiophen-2-ylcyclohexyl]piperidine |
| InChI | InChI=1S/C16H25NS/c1-14-8-3-4-10-16(14,15-9-7-13-18-15)17-11-5-2-6-12-17/h7,9,13-14H,2-6,8,10-12H2,1H3/t14-,16+/m0/s1 |
| InChIKey | DKFAAPPUYWQKKF-GOEBONIOSA-N |
| SMILES | CC1CCCCC1(C2=CC=CS2)N3CCCCC3 |
| Reference | </br>1:Altered mental status and end organ damage associated with the use of gacyclidine: a case series. Chenoweth JA, Gerona RR, Ford JB, Sutter ME, Rose JS, Albertson TE, Clarke SO, Owen KP.J Med Toxicol. 2015 Mar;11(1):115-20. doi: 10.1007/s13181-014-0415-2. PMID: 25048606 Free PMC Article</br>2:Gacyclidine improves the survival and reduces motor deficits in a mouse model of amyotrophic lateral sclerosis. Gerber YN, Privat A, Perrin FE.Front Cell Neurosci. 2013 Dec 27;7:280. doi: 10.3389/fncel.2013.00280. eCollection 2013. PMID: 24409117 Free PMC Article</br>3:Effects of extracochlear gacyclidine perfusion on tinnitus in humans: a case series. Wenzel GI, Warnecke A, Stöver T, Lenarz T.Eur Arch Otorhinolaryngol. 2010 May;267(5):691-9. doi: 10.1007/s00405-009-1126-1. Epub 2009 Oct 22. PMID: 19847455 </br>4:Neuroprotective effect of gacyclidine. A multicenter double-blind pilot trial in patients with acute traumatic brain injury. Lepeintre JF, D/’Arbigny P, Mathé JF, Vigué B, Loubert G, Delcour J, Kempf C, Tadié M.Neurochirurgie. 2004 Jun;50(2-3 Pt 1):83-95. PMID: 15213636 </br>5:Pharmacokinetics of gacyclidine enantiomers in plasma and spinal cord after single enantiomer administration in rats. Hoizey G, Kaltenbach ML, Dukic S, Lamiable D, Millart H, D/’Arbigny P, Vistelle R.Int J Pharm. 2001 Oct 23;229(1-2):147-53. PMID: 11604267 </br>6:Gacyclidine (Beaufour-Ipsen). Mitha AP, Maynard KI.Curr Opin Investig Drugs. 2001 Jun;2(6):814-9. Review. PMID: 11572662 </br>7:Gacyclidine: a new neuroprotective agent acting at the N-methyl-D-aspartate receptor. Hirbec H, Gaviria M, Vignon J.CNS Drug Rev. 2001 Summer;7(2):172-98. Review. PMID: 11474423 Free Article</br>8:Characterization of /’non-N-methyl-D-Aspartate/’ binding sites for gacyclidine enantiomers in the rat cerebellar and telencephalic structures. Hirbec H, Kamenka JM, Privat A, Vignon J.J Neurochem. 2001 Apr;77(1):190-201. PMID: 11279275 Free Article</br>9:Interaction of gacyclidine enantiomers with /’non-NMDA/’ binding sites in the rat central nervous system. Hirbec H, Kamenka JM, Privat A, Vignon J.Brain Res. 2001 Mar 16;894(2):189-92. PMID: 11251192 </br>10:Efficacy of a new neuroprotective agent, gacyclidine, in a model of rat spinal cord injury. Feldblum S, Arnaud S, Simon M, Rabin O, D/’Arbigny P.J Neurotrauma. 2000 Nov;17(11):1079-93. PMID: 11101210 |
